Clinical development of a dendritic-cell vaccine therapy for acute myeloid leukaemia

Informations projet

AML-VACCiN

N° de convention de subvention: 667713

DOI 10.3030/667713

Projet clôturé

Date de signature de la CE 9 Decembre 2015

Date de début 1 Janvier 2016

Date de fin 30 Septembre 2020

Financé au titre de

• SOCIETAL CHALLENGES - Health, demographic change and well-being

Coût total € 8 278 716,25

Contribution de l’UE € 6 001 482,00

Coordonné par

STICHTING AMSTERDAM UMC
Netherlands

Livrables

Other (1)

Document providing the logo and templates for a uniform corporate look

Websites, patent fillings, videos etc. (2)

Press release on the outcome of the interim analysis on effect DCP-001 vaccination on MRD
Press release on the completion of the Phase IIb study

Documents, reports (2)

Cumulative Expenditure report

Cumulative expenditure report required upon activation of Article 205 GA due to the existence of a 24 month reporting period to be submitted by 30 September 2020

Communication and dissemination plan